In consideration with the recent reports of elevated IL-13 levels observed in patients with UC [6], [33] and alterations in EC cells numbers and 5-HT production accompanying different GI disorders, including IBD, [34] the findings of this study shed light on novel immune-endocrine interactions in the gut that may ultimately lead to improved therapeutic strategies in the battle against pathological intestinal inflammation. The gene discussed is IL13; the disease is inflammatory response.